Background Coronavirus disease 2019 (COVID-19) has killed over 2.5 million people worldwide, but effective care and therapy have yet to be discovered. We conducted this analysis to better understand tocilizumab treatment for COVID-19 patients. Main text We searched major databases for manuscripts reporting the effects of tocilizumab on COVID-19 patients. A total of 25 publications were analyzed with Revman 5.3 and R for the meta-analysis. Significant better clinical outcomes were found in the tocilizumab treatment group when compared to the standard care group [odds ratio ( OR ) = 0.70, 95% confidential interval ( C ): 0.54–0.90, P = 0.007]. Tocilizumab treatment showed a stronger correlation with good prognosis among COVID-19 patients that needed mechanical ventilation ( OR = 0.59, 95% CI , 0.37–0.93, P = 0.02). Among stratified analyses, reduction of overall mortality correlates with tocilizumab treatment in patients less than 65 years old ( OR = 0.68, 95% CI : 0.60–0.77, P < 0.00001), and with intensive care unit patients ( OR = 0.62, 95% CI : 0.55–0.70, P < 0.00001). Pooled estimates of hazard ratio showed that tocilizumab treatment predicts better overall survival in COVID-19 patients ( HR = 0.45, 95% CI : 0.24–0.84, P = 0.01), especially in severe cases ( HR = 0.58, 95% CI 0.49–0.68, P < 0.00001). Conclusions Our study shows that tocilizumab treatment is associated with a lower risk of mortality and mechanical ventilation requirement among COVID-19 patients. Tocilizumab may have substantial effectiveness in reducing mortality among COVID-19 patients, especially among critical cases. This systematic review provides an up-to-date evidence of potential therapeutic role of tocilizumab in COVID-19 management. Graphical abstract Supplementary Information The online version contains supplementary material available at 10.1186/s40249-021-00857-w.
【저자키워드】 COVID-19, Cytokine storm, Tocilizumab, IL-6, 【초록키워드】 Treatment, coronavirus disease, Meta-analysis, Coronavirus disease 2019, therapy, Mortality, intensive care, Prognosis, mechanical ventilation, Tocilizumab, systematic review, database, Clinical outcome, survival, management, therapeutic, Patient, Effectiveness, severe cases, estimate, correlation, Care, patients, predict, COVID-19 patients, Evidence, Analysis, COVID-19 patient, critical cases, evidence of, reduction, Abstract, supplementary material, 95% CI, overall mortality, hazard ratio, lower risk, treatment group, Severe case, reducing mortality, standard care group, manuscript, lower risk of mortality, Effect, effective, analyzed, conducted, provide, less, searched, analyses, Significant, stratified, confidential interval, treatment for COVID-19, 【제목키워드】 Tocilizumab, systematic review, treatment for COVID-19,